Difference between revisions of "Isatuximab (Sarclisa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2020-03-02: Approved in combination with pomalidomide and dexamethasone for adult patients with [[multiple myeloma]] who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. ''(Based on ICARIA-MM)'' |
| − | * | + | *2021-03-31: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] who have received one to three prior lines of therapy. ''(Based on IKEMA)'' |
| + | ==History of changes in EMA indication== | ||
| + | *2020-05-30: Initial authorization | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2020-04-29: Initial notice of compliance | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2020-06-29: Newly indicated for the treatment of relapsed or refractory [[multiple myeloma]]. | ||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf Isatuximab (Sarclisa) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf Isatuximab (Sarclisa) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
| Line 17: | Line 25: | ||
*'''Generic name:''' isatuximab-irfc | *'''Generic name:''' isatuximab-irfc | ||
*'''Brand name:''' Sarclisa | *'''Brand name:''' Sarclisa | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 24: | Line 34: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| + | [[Category:EMA approved in 2020]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
| + | [[Category:Health Canada approved in 2020]] | ||
| + | [[Category:PMDA approved in 2020]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism from NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 2020-03-02: Approved in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (Based on ICARIA-MM)
- 2021-03-31: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. (Based on IKEMA)
History of changes in EMA indication
- 2020-05-30: Initial authorization
History of changes in Health Canada indication
- 2020-04-29: Initial notice of compliance
History of changes in PMDA indication
- 2020-06-29: Newly indicated for the treatment of relapsed or refractory multiple myeloma.
Patient Drug Information
Also known as
- Code name: SAR-650984
- Generic name: isatuximab-irfc
- Brand name: Sarclisa